Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

EncompaSSc: Utvärdering av MTX-474 hos deltagare med diffus kutan systemisk skleros (dcSSc)

1 oktober 2026 uppdaterad av: Mediar Therapeutics

En fas 2-randomiserad, dubbelblind, placebokontrollerad studie för att bedöma säkerheten och effekten av MTX-474 vid behandling av deltagare med diffust kutant systemisk skleros (dcSSc)

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

Participants with dcSSc who meet the study's inclusion and exclusion criteria will be randomly assigned in a 3:2 ratio to receive MTX-474 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved dcSSc therapies (immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents) is permitted under certain criteria. Participants randomized to the MTX-474 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, and a Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. mRSS assessments will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. Spirometry will be performed at screening and Weeks 12. HRCT will be performed at screening and week 24. DLCO will be performed at Screening. Skin biopsies will be performed at Baseline and Week 12. Participants will have blood drawn for safety assessment and to assess Ephrin receptor levels at Screening, Baseline and every 4 weeks until Week 28. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-474.

Studietyp

Interventionell

Inskrivning (Beräknad)

85

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Queensland
      • Southport, Queensland, Australien, 4222
        • Rekrytering
        • Griffith University (Clinical Trial Unit)
        • Kontakt:
        • Huvudutredare:
          • Gerald Tracey
      • Woolloongabba, Queensland, Australien, 4102
        • Rekrytering
        • Veracity Clinical Research
        • Huvudutredare:
          • Lynda Spelman
        • Kontakt:
    • Victoria
      • Heidelberg, Victoria, Australien, 3084
        • Rekrytering
        • Austin Health
        • Huvudutredare:
          • Jessica Leung
        • Kontakt:
      • La Tronche, Frankrike, 38700
        • Har inte rekryterat ännu
        • EncompaSSc site in La Tronche, France
        • Kontakt:
      • Montpellier, Frankrike, 34090
        • Har inte rekryterat ännu
        • EncompaSSc site in Montpellier, France
        • Kontakt:
      • Paris, Frankrike, 75014
        • Har inte rekryterat ännu
        • EncompaSSc site in Paris, France
        • Kontakt:
      • Strasbourg, Frankrike, 67000
        • Har inte rekryterat ännu
        • EncompaSSc site in Strasbourg, France
        • Kontakt:
      • Toulouse, Frankrike, 31059
        • Har inte rekryterat ännu
        • EncompaSSc site in Toulouse, France
        • Kontakt:
      • Vandœuvre-lès-Nancy, Frankrike, 54500
        • Har inte rekryterat ännu
        • EncompaSSc site in Vandœuvre-lès-Nancy, France
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85054
        • Har inte rekryterat ännu
        • EncompaSSc site in Phoenix, AZ
        • Kontakt:
    • California
      • La Jolla, California, Förenta staterna, 92037
        • Har inte rekryterat ännu
        • EncompaSSc site in La Jolla, CA
        • Kontakt:
      • Loma Linda, California, Förenta staterna, 92350
        • Har inte rekryterat ännu
        • EncompaSSc site in Loma Linda, CA
        • Kontakt:
      • Los Angeles, California, Förenta staterna, 90095
        • Rekrytering
        • University of California Los Angeles Scleroderma Center
        • Huvudutredare:
          • Elizabeth Volkmann
        • Kontakt:
      • Newport Beach, California, Förenta staterna, 92663
        • Rekrytering
        • NewportNativeMD, Inc.
        • Huvudutredare:
          • Ryan Klein
        • Kontakt:
      • Palo Alto, California, Förenta staterna, 94304
        • Har inte rekryterat ännu
        • EncompaSSc site in Palo Alto, CA
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • Rekrytering
        • University of Colorado Center for Lungs/Breathing/Scleroderma Clinic
        • Kontakt:
        • Huvudutredare:
          • Melissa Griffith
    • Florida
      • Clearwater, Florida, Förenta staterna, 33765
        • Rekrytering
        • Clinical Research of West Florida
        • Huvudutredare:
          • Rodney Daniel
        • Kontakt:
      • Sarasota, Florida, Förenta staterna, 34239
        • Rekrytering
        • Sarasota Arthritis Center
        • Huvudutredare:
          • Jesse Boodoo
        • Kontakt:
      • Tampa, Florida, Förenta staterna, 33606
        • Rekrytering
        • Clinical Research of West Florida
        • Huvudutredare:
          • John Carter
        • Kontakt:
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 66103
        • Har inte rekryterat ännu
        • EncompaSSc site in Kansas City, KS
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21205
        • Rekrytering
        • Johns Hopkins University
        • Huvudutredare:
          • Laura Hummers
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02115
        • Rekrytering
        • Brigham and Women's Hospital
        • Kontakt:
        • Huvudutredare:
          • Avery LaChance
      • Boston, Massachusetts, Förenta staterna, 02118
        • Rekrytering
        • Boston Medical Center
        • Kontakt:
        • Huvudutredare:
          • Andreea Bujor
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55455
        • Har inte rekryterat ännu
        • EncompaSSc site in Minneapolis, MN
        • Kontakt:
    • New York
      • Brooklyn, New York, Förenta staterna, 11201
        • Rekrytering
        • NYU Langone Health
        • Huvudutredare:
          • David Goddard
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44195
        • Har inte rekryterat ännu
        • EncompaSSc site in Cleveland, OH
        • Kontakt:
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Rekrytering
        • The University of Oklahoma Health Sciences Center
        • Kontakt:
        • Huvudutredare:
          • Aikaterini Thanou
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Har inte rekryterat ännu
        • EncompaSSc site in Philadelphia, PA
        • Kontakt:
      • Pittsburgh, Pennsylvania, Förenta staterna, 15219
        • Rekrytering
        • University of Pittsburgh Medical Center
        • Kontakt:
        • Huvudutredare:
          • Christina Padilla
    • Texas
      • Allen, Texas, Förenta staterna, 75013
        • Rekrytering
        • Stryde Research - DFW
        • Huvudutredare:
          • John Lavery
        • Kontakt:
      • Dallas, Texas, Förenta staterna, 75246
        • Rekrytering
        • Baylor Scott & White Research Institute
        • Kontakt:
        • Huvudutredare:
          • Susan Mathai
      • Houston, Texas, Förenta staterna, 77030
        • Har inte rekryterat ännu
        • EncompaSSc site in Houston, TX
        • Kontakt:
      • Ancona, Italien, 60126
        • Har inte rekryterat ännu
        • EncompaSSc site in Ancona, Italy
        • Kontakt:
      • Catania, Italien, 95123
        • Har inte rekryterat ännu
        • EncompaSSc site in Catania, Italy
        • Kontakt:
      • Genoa, Italien, 16132
        • Har inte rekryterat ännu
        • EncompaSSc site in Genoa, Italy
        • Kontakt:
      • Milan, Italien, 20122
        • Har inte rekryterat ännu
        • EncompaSSc site in Milan, Italy
        • Kontakt:
      • Modena, Italien, 41124
        • Har inte rekryterat ännu
        • EncompaSSc site in Modena, Italy
        • Kontakt:
      • Roma, Italien, 00128
        • Har inte rekryterat ännu
        • EncompaSSc site in Roma, Italy
        • Kontakt:
      • Groningen, Nederländerna, 9713 GZ
        • Har inte rekryterat ännu
        • EncompaSSc site in Groningen, Netherlands
        • Kontakt:
      • Auckland, Nya Zeeland, 2025
        • Rekrytering
        • Aotearoa Clinical Trials
        • Huvudutredare:
          • Mark Sapsford
        • Kontakt:
      • Hamilton, Nya Zeeland, 3204
        • Rekrytering
        • Waikato Hospital
        • Kontakt:
        • Huvudutredare:
          • Kamal Solanki
      • Bydgoszcz, Polen, 85-168
        • Har inte rekryterat ännu
        • EncompaSSc site in Bydgoszcz, Poland
        • Kontakt:
      • Nowa Sól, Polen, 67-100
        • Har inte rekryterat ännu
        • EncompaSSc site in Nowa Sól, Poland
        • Kontakt:
      • Warsaw, Polen, 00-874
        • Har inte rekryterat ännu
        • EncompaSSc site in Warszawa, Poland
        • Kontakt:
      • Warsaw, Polen, 02-507
        • Har inte rekryterat ännu
        • EncompaSSc site in Warszawa, Poland
        • Kontakt:
      • Brasov, Rumänien, 500283
        • Har inte rekryterat ännu
        • EncompaSSc site in Brasov, Romania
        • Kontakt:
      • Bucharest, Rumänien, 030463
        • Har inte rekryterat ännu
        • EncompaSSc site in Bucharest, Romania
        • Kontakt:
      • Bucharest, Rumänien, 041303
        • Har inte rekryterat ännu
        • EncompaSSc site in Bucharest, Romania
        • Kontakt:
      • Timișoara, Rumänien, 300133
        • Har inte rekryterat ännu
        • EncompaSSc site in Timişoara, Romania
        • Kontakt:
      • Barcelona, Spanien, 08003
        • Har inte rekryterat ännu
        • EncompaSSc site in Barcelona, Spain
        • Kontakt:
      • Barcelona, Spanien, 08025
        • Har inte rekryterat ännu
        • EncompaSSc site in Barcelona, Spain
        • Kontakt:
      • Córdoba, Spanien, 14004
        • Har inte rekryterat ännu
        • EncompaSSc site in Córdoba, Spain
        • Kontakt:
      • Málaga, Spanien, 29004
        • Har inte rekryterat ännu
        • EncompaSSc site in Malaga, Spain
        • Kontakt:
      • Valencia, Spanien, 46026
        • Har inte rekryterat ännu
        • EncompaSSc site in Valencia, Spain
        • Kontakt:
      • Coventry, Storbritannien, CV2 2DX
        • Har inte rekryterat ännu
        • EncompaSSc site in Walsgrave Coventry, UK
        • Kontakt:
      • Liverpool, Storbritannien, L7 8XP
        • Rekrytering
        • Royal Liverpool University Hospital
        • Huvudutredare:
          • Marina Anderson
        • Kontakt:
      • London, Storbritannien, SW8 3RN
        • Har inte rekryterat ännu
        • EncompaSSc site in London, UK
        • Kontakt:
      • Westcliff-on-Sea, Storbritannien, SS0 0RY
        • Har inte rekryterat ännu
        • EncompaSSc site in Westcliff-on-Sea, UK
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Diagnosis of diffuse cutaneous systemic sclerosis, classified according to 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)

  2. Participant is either:

    1. Within 2 years of their first non-Raynaud's symptom and their mRSS is >7; OR
    2. >2 and ≤5 years from their first non-Raynaud's symptom, their mRSS is between 10 and 30, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS on exams performed by the same clinician, or (2) they were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done; OR
    3. >5 and ≤10 years from their first non-Raynaud's symptom, their mRSS is between >15 and ≤25, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS, or (2) were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done.
  3. Participant is ≥18 years of age at time of signing the ICF.

  4. Able to understand the study and provide a signed, written ICF

  5. Able to read and understand the language of the ICF and other study-related materials

  6. Forced vital capacity (FVCpp) of ≥45 pp10

  7. Have diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥30 percent predicted at Screening

  8. Willing and able to complete all protocol-required study visits and procedures

  9. Participants of childbearing potential must have a negative serum pregnancy test at Screening.

  10. All participants with reproductive potential must agree to use and follow medically approved, highly effective methods of contraception during treatment and until 5 half-lives or 125 days after the last dose, whichever is longer

Exclusion Criteria:

  1. Concomitantly have another serious medical illness, which, in the opinion of the Investigator, would interfere with the participant's ability to complete the study

  2. Participant is currently on immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents detailed as follows:

    1. Immunosuppresive agents: Cyclophosphamide (IV or oral if used in the 6 months prior to Screening), calcineurin inhibitors (if used in the 30 days prior to Screening), azathioprine (if used in the 30 days prior to Screening), Janus-kinase inhibitors (if used in the 30 days prior to Screening), rituximab (if used in the 6 months prior to Screening), tocilizumab (if used in the 60 days prior to Screening) or any other biologic Disease-Modifying Antirheumatic Drugs (DMARD, if used in the last 30 days or 3 half-lives prior to Screening, whichever is longer)
    2. Antifibrotic agents: nintedanib or pirfenidone (if used in the 30 days prior to Screening). Also, exclusionary if used within 3 months of Screening are tyrosine-kinase inhibitors with recognized anti-fibrotic activity (imatinib, nilotinib, etc.)
    3. Systemic glucocorticoids: equivalent doses of prednisone greater than 10 mg/day (≤10 mg/day allowed). Has received any pulse intramuscular (IM) or intravenous (IV) steroid within 1 month of Screening
    4. Other agents:

    i. mycophenolate mofetil unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; ii. mycophenolic acid unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; iii. hydroxychloroquine unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study; and iv. methotrexate unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study.

  3. Previous or planned hematopoietic stem cell or solid organ transplantation

  4. Previous treatment with chimeric antigen receptor (CAR)-T/CAR-NK therapy

  5. Clinically significant PAH as determined by the Investigator at, or prior to first day of dosing (Baseline)

  6. Current use of PAH medication (endothelin receptor antagonists, prostacyclin analogues, soluble guanylate cyclase stimulators) excluding calcium channel blockers and phosphodiesterase-5 inhibitors

  7. Pregnant or currently breastfeeding

  8. Aspartate transaminase (AST) or alanine transaminase (ALT) >2.0 upper limit of normal

  9. Creatinine clearance <45mL/min

  10. History of myocardial infarction, angina or congestive heart failure

  11. International normalized ratio >2 or partial thromboplastin time >1.5 × upper limit of normal

  12. Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

  13. History of clinically significant thrombotic event within 12 months prior to Screening

  14. Positive anticentromere antibody

  15. Systemic sclerosis renal crisis within 12 months prior to Screening

  16. Confirmed diagnosis of overlap syndrome, systemic lupus erythematosus with anti-double strand (ds)DNA antibody, rheumatoid arthritis with anti-cyclic citrullinated peptide (anti-CCP) antibody, or systemic sclerosis mimics (eosinophilic fasciitis, scleromyxedema) at the time of inclusion in the study

  17. Known malignancy or history of malignancy within 5 years of Screening other than non-melanoma skin cancer and in situ cervical cancer

  18. Major surgery within 8 weeks prior to Screening or planned surgery during study period

  19. Unable to routinely access veins for blood draws and IV infusions

  20. Currently receiving another experimental agent or participating in another clinical trial. If a participant has recently received another experimental agent, then the last dose must have been at least 5 half-lives or 30 days (whichever is longer) prior to Screening

  21. History of myocardial infarction, angina or congestive heart failure

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo

Placebo

Placebo

Experimentell: MTX-474

MTX-474

Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline in Modified Rodnan Skin Score (mRSS)
Tidsram: Baseline to week 24

Mean change from baseline to week 24 in the modified Rodnan Skin Score, a clinician-assessed measure of skin thickness across 17 body areas.

Unit of measure: Score (range 0-51)

Baseline to week 24

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of participants with a gene signature response in skin biopsy
Tidsram: 12 weeks

Proportion of participants in each arm (MTX-474 and placebo) demonstrating a dcSSc gene expression signature response on skin biopsy at Week 12.

Unit of Measure: Participants (%)

12 weeks
Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests
Tidsram: Baseline through end of study (week 28)

Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests Unit of Measure: Participants (%)

Baseline through end of study (week 28)
Number of participants with dose interruptions or treatment discontinuations due to adverse events
Tidsram: Baseline through end of study (week 28)

Number of participants with dose interruptions or treatment discontinuations due to adverse events Unit of Measure: Participants (%)

Baseline through end of study (week 28)
Safety and tolerability of MTX-474 in participants with dcSSc: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs)
Tidsram: Baseline through end of study (week 28)

Incidence, seriousness, and severity of TEAEs and TRAEs as determined by investigator assessment.

Unit of measure: Participants (%)

Baseline through end of study (week 28)
Serum concentration of MTX-474 at sparse PK time points
Tidsram: Baseline to week 28

Serum MTX-474 concentrations collected at predefined sparse PK time points to support population pharmacokinetic (popPK) analysis Unit of Measure: ng/mL

Baseline to week 28
Clearance (CL) of MTX-474
Tidsram: Baseline to week 28

Clearance of MTX-474 calculated from serial PK sampling using noncompartmental analysis Unit of Measure: L/hour

Baseline to week 28
Terminal elimination half-life (t½) of MTX-474
Tidsram: Baseline to week 28

Terminal elimination half-life of MTX-474 derived from serial PK sampling. Unit of Measure: Hours

Baseline to week 28
Area under the plasma concentration-time curve (AUC) of MTX-474
Tidsram: Baseline to week 28

AUC of MTX-474 calculated from serial PK sampling using noncompartmental analysis.

Unit of Measure: ng·h/mL

Baseline to week 28

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of participants with a response on the revised American College of Rheumatology Composite Response Index in Systemic Sclerosis (rACR-CRISS)
Tidsram: Baseline to week 24

Proportion of participants achieving rACR-CRISS composite response Unit of Measure: Participants (%)

Baseline to week 24
Change from baseline in Physician Global Assessment (PhGA) of disease status
Tidsram: Baseline to week 24

Mean change from baseline to week 24 in the physician global assessment (phGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease)

Baseline to week 24
Change from baseline in Patient Global Assessment (PtGA) of disease status
Tidsram: Baseline to week 24

Mean change from baseline to week 24 in the patient global assessment (PtGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease)

Baseline to week 24
Change from baseline in percent predicted forced vital capacity (FVCpp)
Tidsram: Baseline to week 24

Mean change from baseline to week 24 on percent predicted forced vital capacity (FVCpp) Unit of Measure: Percent predicted (%)

Baseline to week 24
Change from baseline in quantitative interstitial lung disease (QILD) score by high-resolution computed tomography (HRCT)
Tidsram: Baseline to week 24

Mean change from baseline to week 24 in the QILD score by high resolution computed tomography scan (HRCT) in each arm Unit of Measure: Units on QILD score (0-100 scale; higher score = greater fibrosis)

Baseline to week 24
Change from Baseline in free EphrinB2 levels
Tidsram: Baseline to week 24

Median change from baseline to Week 24 in serum free EphrinB2 levels in each treatment arm.

Unit of Measure: pg/mL

Baseline to week 24
Change from baseline in forced vital capacity (FVC) by EphrinB2 levels
Tidsram: Baseline to week 24

Mean change from baseline to Week 24 in FVC, analyzed by baseline EphrinB2 levels, in the subset of participants with interstitial lung disease (ILD).

Unit of Measure: Percent predicted (%)

Baseline to week 24
Proportion of participants achieving rACR-CRISS response by EphrinB2 levels
Tidsram: Up to 24 weeks

Proportion of participants achieving a response on the revised ACR Composite Response Index in Systemic Sclerosis (rACR-CRISS), stratified by baseline EphrinB2 levels.

Unit of Measure: Participants (%)

Up to 24 weeks
To assess the presence, titer and impact of antidrug antibodies (ADA) against MTX-474
Tidsram: Baseline to week 28

Samples will be collected from baseline until Week 28 to assess the rate at which antibodies develop to the study drug Unit of Measure: Titer units

Baseline to week 28
Change from baseline in expression of total and phosphorylated EphB2, EphB3, and EphB4 receptors in skin
Tidsram: Baseline to Week 12

Mean change from baseline to Week 12 in total and phosphorylated EphB2, EphB3, and EphB4 receptor expression in skin biopsy samples.

Unit of Measure: Relative expression units (fold change from baseline)

Baseline to Week 12
Change from baseline in transcriptomic profile
Tidsram: Baseline to Week 12

Change from baseline to Week 12 in global transcriptomic profile via bulk RNA sequencing analysis of skin biopsies in each arm.

Unit of Measure: Differential gene expression (log₂ fold change)

Baseline to Week 12
Change from baseline in serum biomarkers of organ involvement
Tidsram: Baseline to weeks 12 and 24

Change from baseline to Weeks 12 and 24 in serum levels biomarkers, including but not limited to, ProC3 and IL-6 associated with organ involvement Unit of Measure: ng/mL (or unit per biomarker)

Baseline to weeks 12 and 24
Change from baseline in fatigue symptoms (FACIT-Fatigue score)
Tidsram: Baseline to week 24

Mean change from baseline to Week 24 in fatigue symptoms as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale.

Unit of Measure: Units on FACIT-Fatigue scale (range 0-52; higher score = less fatigue)

Baseline to week 24
Change from baseline in gastrointestinal (GI) symptoms (UCLA SCTC GIT 2.0 score)
Tidsram: Baseline to week 24

Mean change from baseline to Week 24 in GI symptom burden assessed by the UCLA SCTC GIT 2.0 questionnaire.

Unit of Measure: Units on UCLA SCTC GIT 2.0 total score (range 0-3; higher score = worse symptoms)

Baseline to week 24
Change from baseline in anxiety and depression symptoms (HADS)
Tidsram: Baseline to week 24

Mean change from baseline to Week 24 in symptoms of anxiety and depression measured by the HADS instrument.

Unit of Measure: Units on Hospital Anxiety and Depression Scale (HADS total and subscale scores; range 0-21 per subscale; higher score = worse symptoms)

Baseline to week 24
Change from baseline in HAQ-DI
Tidsram: Baseline to week 24

Mean change from Baseline in functional disability as assessed by HAQ-DI. Unit of measure: Score (0-3 scale)

Baseline to week 24

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

16 april 2026

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 december 2028

Studieregistreringsdatum

Först inskickad

18 november 2025

Först inskickad som uppfyllde QC-kriterierna

12 december 2025

Första postat (Faktisk)

17 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • MTX-474-S201
  • 2025-523288-39 (EudraCT-nummer)
  • 2025 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera